CTIC — CTI Biopharma Cashflow Statement
0.000.00%
Last trade - 00:00HealthcareSpeculativeMid Cap
- $1.20bn
- $1.26bn
- $53.95m
Annual cashflow statement for CTI Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -29.4 | -40 | -52.5 | -97.9 | -93 |
| Depreciation | |||||
| Non-Cash Items | 1.98 | 3.89 | 12.1 | 4.63 | 17.8 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -13 | 7.76 | -2.42 | 7.86 | -7.92 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -39.8 | -27.8 | -42.2 | -84.9 | -81.2 |
| Capital Expenditures | -0.033 | 0 | -0.017 | 0 | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -30.5 | 28.1 | -9.6 | 12 | -73.9 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -30.5 | 28.1 | -9.62 | 12 | -73.9 |
| Financing Cash Flow Items | -0.289 | -0.275 | 0 | 47.9 | 53.7 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 63.5 | -5.61 | 61.1 | 97.9 | 120 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -6.78 | -5.29 | 9.25 | 25.1 | -35 |